Linear Stapler Versus Circular Stapler in Esophagojejunostomy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorNanchong Central Hospital

About this trial

With the development of stapler devices, various methods of esophagojejunostomy after laparoscopic total gastrectomy were evoluated. Which stapler is more advantageous has not been determined. At present, the most commonly used is linear stapler or Circular stapler in esophagojejunostomy. However, there is still a lack of reliable evidence for the selection of the two staplers. The purpose of this study is to explore the advantages of linear staper versus circular stapler in esophagojejunostomy for patients with gastric cancer who underwent total gastrectomy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Histologically confirmed adenocarcinoma of the stomach, T1-T4 stages.

Eastern Cooperative Oncology Group performance status of 0 or 1.

Adequate organ function.

Disqualifiers

Patients had distant metastasis.

oesophageal invasion of more than 3 cm.

Borrmann type 4 or large (more than 8 cm) type 3 carcinoma.

Previous chemotherapy or radiation therapy for any other malignancies.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Linear stapler

    Device

    Linear stapler is adopted in esophagojejunostomy

  • Circular stapler

    Device

    Circular stapler is adopted in esophagojejunostomy

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Linear stapler groupExperimental treatment 1 intervention
Group B: Circular stapler groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Surgical complication

All surgical complication after laparoscopic total gastrectomy

Time frame
6 months

Secondary outcomes

1

Operation duration

operation time

Time frame
1 day

Other outcomes

1

hospitalization cost

the cost in hospitalization

Time frame
2 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.